Tonix Pharmaceuticals Holding Corp. TNXP
3.33 USD -0.54 (-14.08%)
Nov 12, 2026, 2:51 PM EST
3.31 Day range 3.96
3.31 52-week range 20.56
- YTD
- -78.71%
- 1 year
- -81.24%
News
marketbeat.com Tonix Pharmaceuticals' TONMYA Sales Jump 37% as Insurance Coverage Expands Tonix Pharmaceuticals NASDAQ: TNXP said sales of its fibromyalgia treatment TONMYA rose 37% in the third quarter, as the company expanded insurance access and increased its sales force.
seekingalpha.com Tonix Pharmaceuticals Holding Corp. (TNXP) Q3 2026 Earnings Call Transcript Tonix Pharmaceuticals Holding Corp. (TNXP) Q3 2026 Earnings Call Transcript
marketbeat.com What Tonix Pharmaceuticals (TNXP) Said on Its Q3 Earnings Call Tonix Pharmaceuticals NASDAQ: TNXP reported approximately $15 million in third-quarter sales of its fibromyalgia drug TONMYA, up 37% from the previous quarter, as insurance coverage expanded and…
benzinga.com Tonix Pharmaceuticals Q3 2026 Earnings Call Transcript Tonix Pharmaceuticals (NASDAQ:TNXP) reported third-quarter financial results on Monday. The transcript from the company’s third-quarter earnings call has been provided below.Benzinga APIs provide…
benzinga.com Tonix Pharmaceuticals Q3 EPS $(2.89) Misses $(2.31) Estimate, Sales $17.200M Beat $16.717M Estimate Tonix Pharmaceuticals (NASDAQ:TNXP) reported quarterly losses of $(2.89) per share which missed the analyst consensus estimate of $(2.31) by 25.11 percent. This is a 19.5 percent increase over losses…
globenewswire.com Tonix Pharmaceuticals Reports Third Quarter 2026 Financial Results and Operational Highlights Third quarter TONMYA® net sales of approximately $15 million, up 37% from the second quarter Approximately $163 million in cash and cash equivalents as of September 30, 2026 Strategic focus on…
benzinga.com Tonix Pharma Presents Data From Analysis Of Phase 3 RELIEF And RESILIENT Studies Of TONMYA For Treatment Of Fibromyalgia In Adults, At IASP 2026 World Congress TONMYA improved Fibromyalgia Impact Questionnaire-Revised (FIQR) symptoms and function scores versus placebo in both domains at Week 14 in RELIEF and RESILIENT Phase 3 pivotal studiesTonix…
benzinga.com Canaccord Genuity Initiates Coverage On Tonix Pharmaceuticals with Buy Rating, Announces Price Target of $18 Canaccord Genuity analyst Gary Nachman initiates coverage on Tonix Pharmaceuticals (NASDAQ:TNXP) with a Buy rating and announces Price Target of $18.
benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session Gainers Pharvaris (NASDAQ:PHVS) stock moved upwards by 19.4% to $36.9 during Wednesday's pre-market session. The market value of their outstanding shares is at $2.0 billion. CalciMedica (NASDAQ:CALC)…
benzinga.com Tonix Pharmaceuticals To Present Effects Of TONMYA On Fibromyalgia Symptoms And Physical Function At The World Congress On Pain, October 26-30 TONMYA was approved by the U.S. Food and Drug Administration on August 15, 2025, and commercially launched in the U.S. on November 17, 2025.Poster Presentation DetailsTitle: Cyclobenzaprine HCl…
benzinga.com Tonix Pharmaceuticals Says Dr. Reddy's Files ANDA With Paragraph IV Patent Certification For Generic TONMYA On Oct 1; Paragraph IV Certification Challenges Four TONMYA Patents Listed In FDA Orange Book; Co Intends To Enforce TONMYA Intellectual Property Rights On October 1, 2026, Tonix Pharmaceuticals Holding Corp. (the "Company") received a notice (the "Notice") from Dr. Reddy’s Laboratories Ltd. and Dr. Reddy’s Laboratories, Inc. (collectively,- benzinga.com Tonix Pharmaceuticals Announces Second Major Managed Medicare Agreement For TONMYA Agreement for the treatment of fibromyalgia in adults that is effective immediately, adding approximately 21 million Medicare lives (38% of approximately 55 million Medicare lives in the U.S.).…
- benzinga.com Tonix Pharmaceuticals Q2 EPS $(2.44) Beats $(2.64) Estimate, Sales $13.544M Beat $7.723M Estimate Tonix Pharmaceuticals (NASDAQ:TNXP) reported quarterly losses of $(2.44) per share which beat the analyst consensus estimate of $(2.64) by 7.58 percent. This is a 36.79 percent increase over losses…
benzinga.com Tonix Pharma Receives Official Minutes From Type C Meeting With FDA To Discuss Plans For Adaptive Phase 2 Field Study Of TNX-4800 To Prevent Lyme Disease In Adults In US Alignment with FDA on key elements of the study design support planned start of the Phase 2 study in the first quarter of 2027Long-acting monoclonal antibody TNX-4800 is a rapidly acting alternative…
benzinga.com Tonix Pharma Announces Publication Of Monkeypox Study In Journal Of Virology, Peer-Reviewed Publication Of ASM Data show clade IIb from 2022 outbreak is 100 to 100,000-fold less virulent than clade IIa from 2003 outbreakThree new models for investigating mpox infection and pathogenesis identifiedTonix is…- benzinga.com Tonix Secures Medicare Coverage For Fibromyalgia Drug TONMYA, Expands TONMYA Coverage To 145M Lives By 2027 Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) ("Tonix" or "the Company"), a fully integrated, commercial-stage biotechnology company, today announced a major managed Medicare agreement for TONMYA®
benzinga.com This Keurig Dr Pepper Analyst Turns Bullish; Here Are Top 4 Upgrades For Thursday Top Wall Street analysts changed outlook on top names. See all changes incl. upgrades, downgrades & initiations on analyst ratings page.
benzinga.com This PVH Analyst Turns Bearish; Here Are Top 3 Downgrades For Thursday Wall Street analysts change outlook on top names, with downgrades and initiations. See analyst ratings page for complete view.
benzinga.com This Tonix Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday Analysts changed outlook on top names, including Intel and Arrow Financial. See ratings page. TNXP stock may be worth considering, analysts say.
benzinga.com Raymond James Initiates Coverage On Tonix Pharmaceuticals with Strong Buy Rating, Announces Price Target of $26 Raymond James analyst Tiago Fauth initiates coverage on Tonix Pharmaceuticals (NASDAQ:TNXP) with a Strong Buy rating and announces Price Target of $26.
benzinga.com Tonix Shares Jump After Landing Second Commercial Payer Agreement For TONMYA Tonix Pharmaceuticals Holding shares are trading higher Monday after securing second commercial payer agreement for fibromyalgia drug TONMYA.
benzinga.com Tonix Pharmaceuticals Enters Agreement With A Group Purchasing Organization To Provide Coverage For TONMYA To An Additional ~17M U.S. Commercial Lives From June 1 Agreement with second leading group purchasing organization (GPO), effective June 1, 2026, provides access to approximately 17 million additional U.S. commercial lives (10% of the ~177 million…- benzinga.com Tonix Pharma Presents Data From Real-World Claims Analysis Of Opioid Use In US Adults With Fibromyalgia At 2026 ASCP Annual Meeting Real-world analysis of three years of closed claims data from Symphony Health, focused on the third year of the study (2023-2024), comprised of more than 261,000 U.S. adults with fibromyalgiaData…
- benzinga.com Tonix Pharmaceuticals' TNX-1500 Shows Favorable Safety Profile In Phase 1 Study As Phase 2 Kidney Transplant Trial Set For 2nd Half 2026 Phase 1 data support TNX-1500 as a potentially first-in-class, best-in-class, third-generation anti-CD40L monoclonal antibody for the prevention of kidney transplant rejectionPhase 2…
- benzinga.com Tonix Pharmaceuticals' ISPOR 2026 Data Show 93.2% Comorbidity Burden And $29,896 Annual Inpatient Costs Among Fibromyalgia Patients Real-world analysis of three years of closed claims data from Symphony Health focused on the third year of the study (2023-2024), comprised of more than 261,000 U.S. adults with fibromyalgiaData…
- benzinga.com Tonix Pharmaceuticals Q1 EPS $(2.93) Misses $(2.43) Estimate, Sales $6.878M Beat $6.100M Estimate Tonix Pharmaceuticals (NASDAQ:TNXP) reported quarterly losses of $(2.93) per share which missed the analyst consensus estimate of $(2.43) by 20.58 percent. This is a 3.17 percent decrease over losses…
benzinga.com Why Tonix Pharmaceuticals Shares Are Rallying Wednesday Tonix Pharmaceuticals Holding shares are trading higher Wednesday after announcing commercial payer coverage for fibromyalgia drug TONMYA.- benzinga.com Tonix Pharmaceuticals Announced An Agreement Effective May 1, 2026, With Group Purchasing Organization For Tonmya (Cyclobenzaprine HCL Sublingual Tablets) Agreement with leading group purchasing organization (GPO) provides access to approximately 35 million U.S. commercial lives (20% of ~177 million commercial lives in the U.S.)TONMYA (cyclobenzaprine…
- benzinga.com TD Cowen Initiates Coverage On Tonix Pharmaceuticals with Buy Rating, Announces Price Target of $22 TD Cowen analyst Stacy Ku initiates coverage on Tonix Pharmaceuticals (NASDAQ:TNXP) with a Buy rating and announces Price Target of $22.
- benzinga.com Tonix Pharma Presents Phase 1 Data And Plans For Adaptive Phase 2 Field Study Of TNX-4800 For Prevention Of Lyme Disease In US At 4th Annual Ticks And Tickborne Diseases Symposium Company on track to initiate a randomized, double-blind, placebo-controlled, adaptive Phase 2 field study in the first half of 2027, pending FDA agreementPhase 2 field study expected to test a…
benzinga.com Tonix Pharma Announces Oral Presentation And Two Poster Presentations On Preclinical Immuno-Oncology Portfolio At AACR Annual Meeting 2026 TNX-1700 (TFF2-albumin fusion protein) reversed aging-associated gastric inflammation and significantly attenuated tumor progression in aged gastric microenvironment in preclinical modelsTNX-1700…- benzinga.com Tonix Pharmaceuticals Announces Publication Of The Paper "Steady-State Pharmacokinetic Properties Of TNX-102 SL, A Sublingual Tablet Formulation Of Cyclobenzaprine Hydrochloride (HCl), With Daily Dosing In Healthy Volunteers: A Randomized, Open-label Trial," In The Journal 'Clinical Pharmacology In Drug Development' The publication reports findings from a single-center, randomized, open-label, multiple-dose, parallel-group pharmacokinetic study conducted in 60 healthy adult volunteers. Participants were…
- benzinga.com Tonix Pharmaceuticals Says Phase 1 Data of TNX-4800 (mAb 2217LS) For Preventing Lyme Disease Demonstrated Safety, Tolerability, And Pharmacokinetics Supportive Of Approximately Four Months Protection Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) ("Tonix" or the "Company"), a fully integrated, commercial biotechnology company, announced Phase 1 data of TNX-4800 (formerly known as mAb…
benzinga.com Tonix Pharmaceuticals Stock Hits New 52-Week Low: What's Driving The Action? Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) shares are trading lower Monday morning, hitting a fresh 52-week low as investors weigh a new SEC filing alongside a biotech pipeline update from…- benzinga.com Tonix Announces First Participant Dosed In Phase 1 Investigator-Initiated Study To Evaluate Effect Of TNX-1900 On Trigeminal Nerve-Mediated Vasodilation Of Forehead Using Capsaicin As Well As Electrical Stimulation Intranasal oxytocin blocks the release of calcitonin gene-related peptide (CGRP) in animal models and is the core technology of TNX-1900 for craniofacial pain conditions, including migraine and…
- benzinga.com Tonix Pharmaceuticals Presents Phase 1 Data On TNX-4800, Long-Acting Human mAb Targeting OspA Of Borrelia Burgdorferi At World Vaccine Congress Washington 2026 Monday, March 30: Phase 1 data on TNX-4800 (long-acting anti-Borrelia OspA human monoclonal antibody) for the seasonal prevention of Lyme disease Wednesday, April 1: Animal and in vitro studies on…
benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session 
benzinga.com Tonix Pharmaceuticals Says Prescriptions For Chronic Pain Drug Top 4,200 Since Launch Tonix Pharmaceuticals beats expectations, and Tonmya prescriptions grow, with over 4,200 prescriptions since launch.- benzinga.com Tonix Pharma Announces Two Oral Presentations On TONMYATM, Investigated As TNX-102 SL, At 8th International Congress On Controversies In Fibromyalgia Company launched TONMYA, approved by the FDA as a treatment for fibromyalgia, in November 2025In post hoc analysis of the pivotal RESILIENT study, TONMYA produced rapid pain relief as early as Day 2…
- benzinga.com Tonix Pharmaceuticals Revealed Data On TONMYATM At The 2026 American Academy of Pain Medicine PainConnect Annual Meeting, in Salt Lake City, Utah; Treatment With TONMYA Provided Statistically Significant Pain Reduction In Two Phase 3 Trials And Was Generally Well Tolerated Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) ("Tonix" or the "Company"), a fully integrated, commercial biotechnology company, presented data on TONMYATM (cyclobenzaprine HCl sublingual…
- benzinga.com Tonix Pharmaceuticals Announces Publication Of Clinical Studies Of TONMYA In Medical Journal TONMYA™ was investigated as TNX-102 SL (cyclobenzaprine HCl sublingual tablets) and approved by the U.S. Food and Drug Administration (FDA) on August 15, 2025, for the treatment of fibromyalgia in…
benzinga.com Tonix Pharmaceuticals Stock Dips After Nasdaq Uplisting Tonix shares fell 2% premarket after the Nasdaq Global Select uplisting, with technical indicators signaling short-term weakness.- benzinga.com Tonix Pharmaceuticals Presents Data On TONMYA, Which Was Investigated As TNX-102 SL, At 2026 Non-Opioid Pain Therapeutics Summit TONMYA demonstrated significant reduction in fibromyalgia pain compared with placebo in the Phase 3 RESILIENT studyUnique sublingual formulation designed for bedtime dosing bypasses first-pass…
benzinga.com 10 Health Care Stocks With Whale Alerts In Today's Session 
benzinga.com Tonix Unveils Once-Yearly Lyme Prevention Antibody, Eyes FDA Talks In 2026 TNXP announced updates on TNX-4800, a long-acting mAb targeting Lyme disease. Seeking FDA meeting in 2026.- benzinga.com Tonix Sells 615,025 Shares at $16.26 Each in $20M Stock Deal With Point72 Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) ("Tonix" or the "Company"), a fully-integrated commercial stage biotechnology company, today announced it has entered into a securities purchase…
- benzinga.com Tonix Pharmaceuticals Announces Plans To Meet FDA In 2026 To Mull TNX-4800 Phase 2/3 Development Options Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) ("Tonix" or the "Company"), a fully-integrated commercial stage biotechnology company, today announced program updates on TNX-4800 (formerly known as…
- benzinga.com Tonix Pharma Announces Licensing Exclusive Worldwide Rights To TNX-4900, Small-Molecule S1R Antagonist With Demonstrated Analgesic Activity In Multiple Models Of Neuropathic Pain Non-opioid analgesic shows efficacy in several animal pain models, including diabetic and chemotherapy-induced neuropathic painCompelling safety and pharmacokinetic profiles in animals support…
- benzinga.com Tonix Pharma Announces FDA Clears IND Application To Support Clinical Development Of TNX-102 SL 5.6 Mg For Treatment Of Major Depressive Disorder In Adults Tonix plans to initiate potential pivotal Phase 2 HORIZON study of TNX-102 SL in adults with major depressive disorder in mid-2026More than 21 million US adults experience a major depressive episode…
benzinga.com Why Tonix Pharmaceuticals (TNXP) Stock Jumped Monday Morning Tonix Pharmaceuticals shares are rising Monday morning after the company announced the U.S. commercial availability of its new drug, TONMYA.